Bio Pharma Dive
NOVEMBER 8, 2024
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could take to “maximizing stockholder value.
Pharmaceutical Technology
NOVEMBER 8, 2024
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 8, 2024
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a narcolepsy drug and CDMO Avid Bioservices agreed to be taken private.
Pharmaceutical Technology
NOVEMBER 8, 2024
The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including Ozempic.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
NOVEMBER 8, 2024
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
Pharmaceutical Technology
NOVEMBER 8, 2024
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 8, 2024
LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority of Pakistan (DRAP) seeking conditional approval for its PIKA Rabies Vaccine for post-exposure prophylaxis (PEP).
pharmaphorum
NOVEMBER 8, 2024
Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.
Pharmaceutical Technology
NOVEMBER 8, 2024
Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex virus type 1 oncolytic virus and a component of MB-109, designed to treat malignant glioma.
pharmaphorum
NOVEMBER 8, 2024
AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities
Pharmaceutical Technology
NOVEMBER 8, 2024
Sonnet BioTherapeutics has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 and SON-1400, expected to advance treatment options for cancer.
Fierce Pharma
NOVEMBER 8, 2024
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. | AstraZeneca confirmed its China president has been detained by Chinese authorities. Pfizer plans to invest $1 billion in China in the next five years. Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte.
Pharmaceutical Technology
NOVEMBER 8, 2024
Advancing to first-in-human clinical trials requires formulation development to design a successful sterile formulation that meets your TPP.
pharmaphorum
NOVEMBER 8, 2024
Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
NOVEMBER 8, 2024
Analysis of future trends highlights that the cold chain logistics sector is at a critical juncture, with tech advancements driving change.
Medical Xpress
NOVEMBER 8, 2024
As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells—which have lost their cancer-fighting oomph—consume this lactic acid, which further saps their energy, according to new research from the University of Pittsburgh and UPMC Hillman Cancer Center.
Pharmaceutical Technology
NOVEMBER 8, 2024
Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of AUR200.
Fierce Pharma
NOVEMBER 8, 2024
Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has
pharmaphorum
NOVEMBER 8, 2024
Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.
Fierce Pharma
NOVEMBER 8, 2024
After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood diso | After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.
Medical Xpress
NOVEMBER 8, 2024
Researchers are releasing the flagship dataset from an ambitious study of biomarkers and environmental factors that might influence the development of type 2 diabetes. Because the study participants include people with no diabetes and others with various stages of the condition, the early findings hint at a tapestry of information distinct from previous research.
Fierce Pharma
NOVEMBER 8, 2024
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that AstraZeneca and Amgen's Tezspire provided a statistically significant and clinically meaningful reduction in polyp size and nasal congestion in patients with severe chronic rhinosinusitis with nasal polyps.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
NOVEMBER 8, 2024
The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health Data Research (HDR) UK – which found that accessing patient data can take months or even years, hampering research into areas like dementia, cancer and heart disease.
Fierce Pharma
NOVEMBER 8, 2024
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and | The company opted not to renew its membership for 2025 following an annual review of its trade group associations, a spokesperson said.
XTalks
NOVEMBER 8, 2024
This blog is the fourth in our series exploring TIME’s “Best Inventions of 2024” list, following our deep dives into some of the most transformative medical devices , pharma and food innovations. Today, we spotlight healthcare inventions transforming clinical and at-home care, selected by TIME for their potential to tackle major healthcare challenges and elevate patient care.
Fierce Pharma
NOVEMBER 8, 2024
With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, accusing the firm behind the opioid addiction treatment Sublocade of “ig | Investment fund Oaktree Capital Management has called for a shakeup of Indivior’s board of directors, referring to the more than 50% stock price drop Indivior has suffered in 2024 as “unacceptable.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
NOVEMBER 8, 2024
Conducting a cybersecurity audit on your pharmaceutical supply chain is crucial for protecting sensitive data. Learn how to properly assess and strengthen your cybersecurity measures with this guide.
Intouch Solutions
NOVEMBER 8, 2024
In an exclusive feature with MM+M , Chief Creative Officer Susan Perlbachs shared insights into Artful Ingenuity, EVERSANA INTOUCH’s latest campaign highlighting the agency’s commitment to data-driven, creative, and AI-powered AOR services. At its core, Artful Ingenuity aims to reinforce EVERSANA INTOUCH’s position as the global agency network that delivers breakthrough thinking and reliable execution.
Fierce Pharma
NOVEMBER 8, 2024
With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. | With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. Now, after several years spent validating its manufacturing platform, the company is expanding in a big way with the debut of a new service line and factory i
Imperical Blog
NOVEMBER 8, 2024
Delays can be small or big, from minor misfortunes that make us late for dinner to major study setbacks that mangle study timelines and jeopardize study goals. While delays in life are expected and inevitable, clinical study delays don’t have to send a trial off… The post Don’t Let Clinical Study Delays Derail Timelines appeared first on Imperial Clinical Research Services Blog.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
173 
Let's personalize your content